SBE-β-CD (Synonyms: 磺丁基-β-环糊精; Sulfobutylether-β-Cyclodextrin)

目录号: HY-17031 纯度: 99.52%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

SBE-β-CD 是磺基丁基醚 β-cyclodextrin 衍生物，其用作赋形剂或助溶剂以增加难溶性活性分子的溶解度。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

SBE-β-CD Chemical Structure

CAS No. : 182410-00-0

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
500 mg	￥500	In-stock
1 g	￥800	In-stock
5 g	￥1600	In-stock
10 g	￥2400	In-stock
25 g	￥4800	In-stock
50 g	现货	询价
> 100 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

MCE 顾客使用本产品发表的 93 篇科研文献

SBE-β-CD 相关产品

•同靶点产品:

•同靶点蛋白产品:

生物活性
实验参考方法
纯度 & 产品资料
参考文献

生物活性	SBE-β-CD is a sulfobutylether β-cyclodextrin derivative used as an excipient or a formulating agent to increase the solubility of poorly soluble agents^[1].
体外研究 (In Vitro)	SBE-β-CD 是一种化学修饰的β-CD，是一种在水性介质中带负电荷的环状亲水性低聚糖。β-CD 功能仅在低浓度下是一种增溶剂，而 SBE7-β-CD 在较宽的浓度范围内表现出很强的增溶作用^[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. SBE-β-CD 相关抗体:
体内研究 (In Vivo)	20% SBE-β-CD 生理盐水：指南 (以下是我们推荐的方案。此方案仅提供指南，应根据您的具体需要进行修改)。 1. 将0.9 g NaCl 溶于100 mL 蒸馏水中，制成澄清的0.9% 盐水溶液。 2. 量取 2 g 干燥的 SBE-β-CD。 3. 将 2 g SBE-β-CD 溶解在 0.9% 盐水中，制成 10 mL 浓度为 20% (w/v) 的溶液.这些可能需要超声波 (20-40 kHz，30 秒，重复 3 次) 或加热 (37°C 约 30 分钟)。如果观察到沉淀，可通过加热至 37°C 并在使用前涡旋来溶解沉淀。 MCE has not independently confirmed the accuracy of these methods. They are for reference only.
分子量	2083-2257
CAS 号	182410-00-0
性状	固体
颜色	White to off-white
中文名称	磺丁基-β-环糊精；磺丁基醚-β-环糊精
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	4°C, sealed storage, away from moisture and light
溶解性数据	细胞实验： H₂O 中的溶解度 : ≥ 100 mg/mL * "≥" means soluble, but saturation unknown. 摩尔计算器稀释计算器 Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol) 质量 = 浓度 × 体积 × 分子量 * Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final) This equation is commonly abbreviated as: C₁V₁ = C₂V₂ 浓度 _(start) C1 × 体积 _(start) V1 = 浓度 _(final) C2 × 体积 _(final) V2 扫码获得动物溶解方案动物溶解方案计算器请输入动物实验的基本信息：给药剂量 mg/kg 动物的平均体重 g 每只动物的给药体积 μL 动物数量只由于实验过程有损耗，建议您多配一只动物的量计算结果工作液所需浓度 : mg/mL 该产品水溶性佳，请具体参考实测水 / PBS / Saline 中的溶解度数据。您所需的储备液浓度超过该产品的实测溶解度，如有需要，请与 MCE 中国技术支持联系。免费服务热线：400-820-3792 E-mail：sales@medchemexpress.cn 技术支持电话：021-58950656 技术支持邮箱：tech@medchemexpress.cn
纯度 & 产品资料	纯度: 99.52% 选择批次： Data Sheet (629 KB) SDS (393 KB) COA (315 KB) HNMR (336 KB) RP-HPLC (217 KB) 产品使用指南 (1538 KB)
参考文献	[1]. Fukuda M, et al.Influence of sulfobutyl ether beta-cyclodextrin (Captisol) on the dissolution properties of a poorly soluble drug from extrudates prepared by hot-melt extrusion.Int J Pharm. 2008 Feb 28;350(1-2):188-196 [Content Brief] [2]. Charman SA, et al. Alteration of the intravenous pharmacokinetics of a synthetic ozonide antimalarial in the presence of a modified cyclodextrin. J Pharm Sci. 2006 Feb;95(2):256-67 [Content Brief]

Animal Administration ^[2]	Rats^[2] A 300 g rat is administered with 1 mL of a 0.1 M SBE-β-CD solution containing 5.64 mg of Compound 1, and assuming an extracellular volume of 90 mL, less than 0.1% of the complex would rapidly dissociate due to the initial effects of dilution. This calculation, combined with the changing blood to plasma ratio in the presence of SBE-β-CD, provides a reasonable explanation for the observed differences in the blood and plasma profiles of Compound 1 after intravenous administration in either the cyclodextrin or cyclodextrin-free formulations. After IV administration of the cyclodextrin formulation, Compound 1 would initially be prevented from distributing into erythrocytes thereby resulting in a whole blood to plasma ratio of less than one. Subsequently, clearance of SBE-β-CD from the circulation would lead to changes in the complexation equilibrium such that the unbound fraction of Compound 1 would increase, thereby reestablishing normal blood to plasma partitioning (i.e. in favour of whole blood) and clearance. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Fukuda M, et al.Influence of sulfobutyl ether beta-cyclodextrin (Captisol) on the dissolution properties of a poorly soluble drug from extrudates prepared by hot-melt extrusion.Int J Pharm. 2008 Feb 28;350(1-2):188-196 [Content Brief] [2]. Charman SA, et al. Alteration of the intravenous pharmacokinetics of a synthetic ozonide antimalarial in the presence of a modified cyclodextrin. J Pharm Sci. 2006 Feb;95(2):256-67 [Content Brief]

Animal Administration
^[2]

Rats^[2]
A 300 g rat is administered with 1 mL of a 0.1 M SBE-β-CD solution containing 5.64 mg of Compound 1, and assuming an extracellular volume of 90 mL, less than 0.1% of the complex would rapidly dissociate due to the initial effects of dilution. This calculation, combined with the changing blood to plasma ratio in the presence of SBE-β-CD, provides a reasonable explanation for the observed differences in the blood and plasma profiles of Compound 1 after intravenous administration in either the cyclodextrin or cyclodextrin-free formulations. After IV administration of the cyclodextrin formulation, Compound 1 would initially be prevented from distributing into erythrocytes thereby resulting in a whole blood to plasma ratio of less than one. Subsequently, clearance of SBE-β-CD from the circulation would lead to changes in the complexation equilibrium such that the unbound fraction of Compound 1 would increase, thereby reestablishing normal blood to plasma partitioning (i.e. in favour of whole blood) and clearance.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献

[1]. Fukuda M, et al.Influence of sulfobutyl ether beta-cyclodextrin (Captisol) on the dissolution properties of a poorly soluble drug from extrudates prepared by hot-melt extrusion.Int J Pharm. 2008 Feb 28;350(1-2):188-196 [Content Brief]

[2]. Charman SA, et al. Alteration of the intravenous pharmacokinetics of a synthetic ozonide antimalarial in the presence of a modified cyclodextrin. J Pharm Sci. 2006 Feb;95(2):256-67 [Content Brief]

SBE-β-CD 相关分类

Others

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

SBE-β-CD182410-00-0Sulfobutylether-β-Cyclodextrin磺丁基-β-环糊精磺丁基醚-β-环糊精Biochemical Assay ReagentsInhibitorinhibitorinhibit

您最近查看的产品:

产品名称：

* 需求量：

* 客户姓名：

* Email：

* 电话：

* 公司或机构名称：

留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。

站点地图隐私声明

沪ICP备15051369号-4

上海工商

沪公网安备31011502019417

沪(浦)应急管危经许[2021]201709(QFYS)

营业执照（三证合一）

SBE-β-CD (Synonyms: 磺丁基-β-环糊精; Sulfobutylether-β-Cyclodextrin)

Customer Review

MCE 顾客使用本产品发表的 93 篇科研文献

SBE-β-CD 相关产品

•同靶点产品:

•同靶点蛋白产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

SBE-β-CD 相关分类

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

SBE-β-CD (Synonyms: 磺丁基-β-环糊精; Sulfobutylether-β-Cyclodextrin)

Customer Review

SBE-β-CD 相关抗体

MCE 顾客使用本产品发表的 93 篇科研文献

SBE-β-CD 相关产品

•同靶点产品:

•同靶点蛋白产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

SBE-β-CD 相关抗体:

摩尔计算器

稀释计算器

SBE-β-CD 相关分类

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z